Back to top
more

Exelixis (EXEL)

(Real Time Quote from BATS)

$36.59 USD

36.59
71,979

-0.22 (-0.60%)

Updated Aug 5, 2025 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis (EXEL) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 86.67% and 21.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Equity Research

    Is Exelixis (EXEL) Poised for a Beat Again in Q2?

    by Zacks Equity Research

    Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.

      Zacks Equity Research

      Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

      by Zacks Equity Research

      The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.

        Zacks Equity Research

        Exelixis (EXEL) Jumps: Stock Rises 8%

        by Zacks Equity Research

        Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

          Zacks Equity Research

          Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

          by Zacks Equity Research

          Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

            Zacks Equity Research

            Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

            by Zacks Equity Research

            European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

              Zacks Equity Research

              Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?

              by Zacks Equity Research

              Investors in Exelixis (EXEL) need to pay close attention to the stock based on moves in the options market lately.

                Zacks Equity Research

                Here's Why You Should Sell Fresenius Medical (FMS) Stock Now

                by Zacks Equity Research

                A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).

                  Zacks Equity Research

                  Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss

                  by Zacks Equity Research

                  Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.

                    Zacks Equity Research

                    Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day

                    by Zacks Equity Research

                    Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day

                      Zacks Equity Research

                      Here's Why You Should Invest in Varian Medical (VAR) Now

                      by Zacks Equity Research

                      Strong fundamentals and solid Q2 results make Varian Medical (VAR) a must buy.

                        Zacks Equity Research

                        Cerner EHR Range Picked by Indiana's FSSA for Patient Care

                        by Zacks Equity Research

                        Cerner (CERN) gains as Indiana FSSA chooses its flagship Cerner Millennium solutions to take better care of patients.

                          Zacks Equity Research

                          Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher

                          by Zacks Equity Research

                          Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.

                            Zacks Equity Research

                            Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

                            by Zacks Equity Research

                            Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

                              Kevin Cook headshot

                              Bull of the Day: Exelixis (EXEL)

                              by Kevin Cook

                              This profitable biotech is growing at over 50% and just went on sale after a clinical trial failure that analysts weren't even modeling

                                David Borun headshot

                                Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.

                                by David Borun

                                Bid U.S. drug makers are seen as largely spared the worst in the Trump Administrations plans to control drug prices.

                                  Ekta Bagri headshot

                                  Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings

                                  by Ekta Bagri

                                  Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.

                                    Ekta Bagri headshot

                                    Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View

                                    by Ekta Bagri

                                    Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.

                                      Ekta Bagri headshot

                                      Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

                                      by Ekta Bagri

                                      Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.

                                        Zacks Equity Research

                                        Here's Why You Should Invest in Intuitive Surgical Right Now

                                        by Zacks Equity Research

                                        Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.

                                          Tirthankar Chakraborty headshot

                                          5 Winning Stocks With Superb Efficiency Level

                                          by Tirthankar Chakraborty

                                          A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                                            Zacks Equity Research

                                            Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected

                                            by Zacks Equity Research

                                            Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.

                                              Zacks Equity Research

                                              Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

                                              by Zacks Equity Research

                                              Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.

                                                Zacks Equity Research

                                                Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag

                                                by Zacks Equity Research

                                                Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.

                                                  Zacks Equity Research

                                                  Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength

                                                  by Zacks Equity Research

                                                  Exelixis (EXEL) posted a strong performance in the first-quarter as lead drug Cabometyx made further inroads in the RCC market.